Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
Retailers could be in for a jolly jump in holiday sales despite headwinds like the U.S.-China trade war and threat of another economic slowdown.Retailread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
Apple isn't trying to blow our minds with groundbreaking new features on the iPhone 11, but is making lots of little improvements each year, this year focusing on cameras and...Technologyread more
The move is the latest sign of the blurring boundaries between big tech and big finance amid challenges for both industries.Financeread more
Pizza Hut is also talking with Kellogg and other suppliers about the plant-based meat trend.Restaurantsread more
Saudi Arabia's defense spending is the world's third-largest — behind the U.S. and China, says Gary Grappo, former U.S. ambassador to Oman.Energyread more
J.P. Morgan's chief quant says oil prices would start to hurt stock prices when they hit the $80 to $85 range.Market Insiderread more
Chinese officials are expected to be in Washington this week to hold consultations with the U.S. ahead of high-level trade talks in October.World Economyread more
The ballot comes at a precarious time for the country's longest serving prime minister, with the right-wing incumbent facing formidable challenges.World Politicsread more
New court filings reveal that Elon Musk's family office spent tens of thousands on a private investigator to dig up details about Thai cave rescue hero Vernon Unsworth, after...Technologyread more
The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.
Governments globally bought Tamiflu, which is manufactured by Swiss pharmaceutical giant Roche, to prepare for flu outbreaks. However, a joint publication by the Cochrane Collaboration, a global not-for-profit organization of academics, and the British Medical Journal (BMJ) found Tamiflu did not cut hospital admissions or reduce flu symptoms.
Roche has criticized the findings, arguing that the report is flawed and that the drug is effective.
The British government has spent £424 million ($703 million) on the drug while the U.S. has spent over $1.3 billion buying reserve antivirals including Tamiflu, according to Reuters. Tamiflu sales were particularly strong back in 2009 when governments sought to ready themselves for the H1N1 "swine flu" pandemic.
The Cochrane Collaboration reviewed trial data on Roche's Tamlifu, as well as GlaxoSmithKline's Relenza, sampling 46 trials in total. The report said, "We identiﬁed problems in the design of many of the studies that we included, which affects our conﬁdence in their results. We found that both drugs shorten the duration of symptoms of inﬂuenza-like illness (unconﬁrmed inﬂuenza or 'the ﬂu') by less than a day."
The report said that Tamiflu did not affect the number of hospitalizations of people inoculated with the drug , and that Tamiflu's "effects on pneumonia and other complications of inﬂuenza, such as bronchitis, middle ear infection (otitis media) and sinusitis, were unreliably reported."
Furthermore, the drug was found to have increased the risk of suffering from nausea and vomiting. The BMJ said Tamiflu's trials were not conducted independent of the drug's manufacturer and that the trials "were against placebo rather than against standard drugs for relieving symptoms, such as paracetamol."
In response, Roche said in a statement: "We firmly stand by the quality and integrity of our data, reflected in decisions reached by 100 regulators across the world and subsequent real-world evidence demonstrating that Tamiflu is an effective medicine in the treatment and prevention of influenza."
Enrica Alteri, the head of medicines evaluation at the European Medicines Agency (EMA), which approved the drug in Europe, said the organization had reviewed the same cases as those studied by the new report and that she stood by the EMA's assessment.
Drug companies do not publish all their data and this report came about after a long fight for further information on Tamiflu.
At a briefing in London, Fiona Godlee, editor of the BMJ, said that obtaining the data had been a "really lengthy cat-and-mouse, Alice in Wonderland, bizarre experience of trying to get data on a drug which governments around the world were busy buying, stockpiling and spending billions of dollars on.
"Why did no-one else demand this level of scrutiny before spending such huge sums on one drug? The whole story gives an extraordinary picture of the entrenched flaws in the current system of drug regulation and drug evaluation."